BR9808424A - Compound, processes for its preparation, for the preparation of intermediates and for the treatment of a mammal, including human beings, pharmaceutical composition, and use of a compound. - Google Patents

Compound, processes for its preparation, for the preparation of intermediates and for the treatment of a mammal, including human beings, pharmaceutical composition, and use of a compound.

Info

Publication number
BR9808424A
BR9808424A BR9808424-0A BR9808424A BR9808424A BR 9808424 A BR9808424 A BR 9808424A BR 9808424 A BR9808424 A BR 9808424A BR 9808424 A BR9808424 A BR 9808424A
Authority
BR
Brazil
Prior art keywords
preparation
compound
processes
pharmaceutical composition
intermediates
Prior art date
Application number
BR9808424-0A
Other languages
Portuguese (pt)
Inventor
Romano Di Fabio
Barbara Bertani
Giuseppe Alvaro
Original Assignee
Glaxo Wellcome Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Spa filed Critical Glaxo Wellcome Spa
Publication of BR9808424A publication Critical patent/BR9808424A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

''COMPOSTO, PROCESSOS PARA A PREPARAçãO DO MESMO, PARA A PREPARAçãO DOS INTERMEDIáRIOS E PARA TRATAMENTO DE UM MAMìFERO, INCLUINDO O SER HUMANO, COMPOSIçãO FARMACêUTICA, E, USO DE UM COMPOSTO''. O enanciómero do ácido (+) E 4-(acetilamino-fenilcarbamoilmetileno)-5,7-dicloro-1,2,3,4-tetraidroqui nolina-2-carboxílico e seu sal, que são antagonistas de aminoácidos excitatórios, para processos para sua preparação, para composições farmacêuticas contendo-os, e para seu uso em medicina.'' COMPOUND, PROCESSES FOR THE PREPARATION OF THE SAME, FOR THE PREPARATION OF INTERMEDIARIES AND FOR TREATING A MAMMALIAN, INCLUDING THE HUMAN BEING, PHARMACEUTICAL COMPOSITION, AND, USE OF A COMPOUND ''. The (+) E 4- (acetylamino-phenylcarbamoylmethylene) -5,7-dichloro-1,2,3,4-tetrahydroquinoline-2-carboxylic acid enanciomer and its salt, which are excitatory amino acid antagonists, for processes for their preparation, for pharmaceutical compositions containing them, and for their use in medicine.

BR9808424-0A 1997-03-26 1998-03-24 Compound, processes for its preparation, for the preparation of intermediates and for the treatment of a mammal, including human beings, pharmaceutical composition, and use of a compound. BR9808424A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9706294.7A GB9706294D0 (en) 1997-03-26 1997-03-26 Heterocyclic compound
PCT/EP1998/001700 WO1998042673A1 (en) 1997-03-26 1998-03-24 Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonist

Publications (1)

Publication Number Publication Date
BR9808424A true BR9808424A (en) 2000-05-23

Family

ID=10809909

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808424-0A BR9808424A (en) 1997-03-26 1998-03-24 Compound, processes for its preparation, for the preparation of intermediates and for the treatment of a mammal, including human beings, pharmaceutical composition, and use of a compound.

Country Status (20)

Country Link
EP (1) EP0971896A1 (en)
JP (1) JP2001518901A (en)
KR (1) KR20010005567A (en)
CN (1) CN1257482A (en)
AP (1) AP9901659A0 (en)
AU (1) AU731394B2 (en)
BR (1) BR9808424A (en)
CA (1) CA2284710A1 (en)
EA (1) EA199900755A1 (en)
GB (1) GB9706294D0 (en)
HU (1) HUP0001661A3 (en)
ID (1) ID24306A (en)
IL (1) IL131919A0 (en)
IS (1) IS5186A (en)
NO (1) NO994679L (en)
NZ (1) NZ337793A (en)
PL (1) PL335865A1 (en)
TR (1) TR199902315T2 (en)
WO (1) WO1998042673A1 (en)
YU (1) YU47699A (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist
DE10132725A1 (en) 2001-07-05 2006-08-03 Grünenthal GmbH Substituted γ-lactone compounds
DE10137487A1 (en) * 2001-08-03 2003-03-27 Gruenenthal Gmbh Substituted 5,6,6a, 11b-tetrahydro-7-oxa-6-aza-benzo [c] fluorene-6-carboxylic acid derivatives
DE10306202A1 (en) 2003-02-13 2004-08-26 Grünenthal GmbH 2-(hetero)aryl-2-(N-((hetero)aryl)-amino)-acetic acid derivatives useful e.g. for treating anxiety, inflammation, allergy, depression, diarrhea or especially pain is NMDA antagonist
JP4360891B2 (en) 2003-12-09 2009-11-11 アルパイン株式会社 Electronic device having broadcast receiving function and display method of electronic program guide in the device
KR101136183B1 (en) 2005-07-22 2012-04-17 모찌다 세이야쿠 가부시끼가이샤 Novel heterocyclidene acetamide derivative
RU2451014C2 (en) * 2005-07-22 2012-05-20 Мотида Фармасьютикал Ко., Лтд. Novel heterocyclidene acetamide derivative
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
JP7305560B2 (en) 2017-06-12 2023-07-10 グリテック， エルエルシー Treatment of depression with NMDA antagonists and D2/5HT2A or selective 5HT2A antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0386839B1 (en) * 1989-03-08 1997-01-15 Merck Sharp & Dohme Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
TR199800531T1 (en) * 1995-09-29 1998-06-22 Glaxo Wellcome Spa Tetrahydroquinolines as NMDA antagonists.
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds

Also Published As

Publication number Publication date
GB9706294D0 (en) 1997-05-14
ID24306A (en) 2000-07-13
PL335865A1 (en) 2000-05-22
TR199902315T2 (en) 2000-05-22
AP9901659A0 (en) 1999-09-30
HUP0001661A3 (en) 2001-12-28
NZ337793A (en) 2001-02-23
JP2001518901A (en) 2001-10-16
NO994679L (en) 1999-11-24
WO1998042673A1 (en) 1998-10-01
IL131919A0 (en) 2001-03-19
AU7209498A (en) 1998-10-20
CN1257482A (en) 2000-06-21
AU731394B2 (en) 2001-03-29
EP0971896A1 (en) 2000-01-19
KR20010005567A (en) 2001-01-15
EA199900755A1 (en) 2000-08-28
NO994679D0 (en) 1999-09-24
HUP0001661A2 (en) 2000-09-28
YU47699A (en) 2001-12-26
CA2284710A1 (en) 1998-10-01
IS5186A (en) 1999-09-17

Similar Documents

Publication Publication Date Title
ES2133785T3 (en) METALOPROTEINASE INHIBITORS.
BR9713489A (en) substituted aminoalkanophosphonic acids
DE122011100032I1 (en) Use of n-substituted pyridones as tumor necrosis factor alpha inhibitors.
DK0643726T3 (en) Human p53 protein peptides for use in compositions that induce human T cell response and human p53 protein
BR9911488A (en) Compound, use of it, pharmaceutical composition, and processes for the treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound
PT99445A (en) PROCESS FOR THE PREPARATION OF MONO-N-SUBSTITUTED 1,4,7,10-TETRAAZACYCLODODEAN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ATE61050T1 (en) PYRIDAZINAMINES EFFECTIVE AGAINST VIRUSES.
EE03969B1 (en) (Methylsulfonyl) phenyl-2- (5H) -furanones, their Use and Pharmaceutical Compositions
BR9709062A (en) Compound, pharmaceutical composition, and, use of a compound.
PT98710A (en) PROCESS FOR THE PREPARATION OF SUBSTITUTED INDOLIL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
BR9406720A (en) Use of a recombinant adenovirus of animal origin Recombinant adenovirus of animal origin and pharmaceutical composition comprising one or more adenoviruses
BR9714358A (en) Derivatives of n- (aryl / heteroaryl) amino acid, pharmaceutical compositions comprising them, and methods for inhibiting the release of beta-amyloid peptide and / or its synthesis by using such compounds
TR199802534T2 (en) Leptin (OB Protein) fragmanlar�
BR0015416A (en) Compositions containing tetraenoic hydroxyieic acid derivatives and methods of use in the treatment of dry eye disorders
BR9812492A (en) Compound, use of it, pharmaceutical formulation, and processes for the treatment of cardiovascular disease, for the treatment of vasoconstriction, and for the preparation of compounds
DE68913762D1 (en) Diaryl compounds as antiatherosclerotic agents.
BR9910329A (en) Compound, pharmaceutical composition, process to stimulate the release of growth hormone from a mammal's pituitary, and use of a compound
FI972308A0 (en) 2-Substituted 1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions containing them and methods for their use
DE3853910D1 (en) MOLECULAR LURE AND THEIR USE.
ATE83376T1 (en) QUINOLINYL ETHER TETRAZOLES AS A MEDICATION FOR THE TREATMENT OF HYPERSENSITIVE DISEASES.
BR9808424A (en) Compound, processes for its preparation, for the preparation of intermediates and for the treatment of a mammal, including human beings, pharmaceutical composition, and use of a compound.
DE69522188D1 (en) Use of substance P antagonist in pharmaceutical composition
NO941681D0 (en) Human IL-4 mutant proteins
BR9813514A (en) Agent for the treatment of keratin fibers
ES2104133T3 (en) COSMETIC OR PHARMACEUTICAL COMPOSITIONS CONTAINING GELEROPHOSPHOLIPIDS DESACLATED FOR TOPICAL USE.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A,7A,8A E 9A

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1892 DE 10/04/2007.